Planet Labs, EchoStar, Robinhood, Summit Therapeutics, BioNTech, CVS Health

Happy Monday. It’s Sept. 8, 2025. These are today’s top moving stocks, a segment of our daily live blog, Stock Market Today. To get updates on how the market is performing, as well as data and insights about the broader U.S. economy, click the link above to find today’s edition.

Satellite imaging company Planet Labs  (PL)  (+39.7%) is today’s best-performing stock, hitting a 52-week high after reporting strong earnings, with revenue up 20%. The company also raised its outlook and, like seemingly all spacefaring firms these days, reported a record backlog.

TheStreet Pro’s Stephen Guilfoyle has a whole write-up about the company this afternoon, which was a one-time member of TheStreet’s “Stocks Under $10” portfolio. However, in light of today’s earnings, Guilfoyle simply said: “I want to own some of this small-cap stock.”

Staying on a satellite note, EchoStar  (SATS)  (+18%) is up today after announcing a deal to sell wireless spectrum to Elon Musk’s SpaceX as part of a $17 billion deal. The acquisition will help Musk’s Starlink satellite business expand its 5G offering, while the acquisition will also help Boost Mobile subscribers access satellite calls.

Shares of competitor Globalstar  (GSAT) (+20%) were up on the sale, as more investors began to marinate on the value of wireless spectrum and price it into the value of various telecom names. Iridium Communications  (IRDM)  (-12.7%) and AST SpaceMobile ASTS (-5.7%) fell.

Robinhood  (HOOD) (+14%) is up after scoring addition to one of Wall Street’s most exclusive clubs: the S&P 500. The brokerage will be flanked by adtech company AppLovin  (APP)  (+11%) and industrial firm Emcor Group  (EME)  (-0.36%).

Check out our Friday coverage on Robinhood and AppLovin’s big addition to the index, how they got in, and what companies could be next:

Related: These two popular tech stocks just got added to the S&P 500

Summit Therapeutics  (SMMT)  (-23.7%) purported to have a potential blockbuster on their hands when they began a trial of ivonescimab in advanced lung cancer. The drug, already approved in China, was floated as a possible competitor to the standard of care, Merck‘s  (MRK)  (-1%) Keytruda.

Those hopes might have been misplaced, as the company’s updated Phase III results in North America and Europe were shown to be weaker than in China. Tumor progression fell just 33% in western markets, compared with the 45% measured in China.